Diana Rudan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Diana Rudan has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Šime Manola
Dubrava University Hospital, Zagreb, Croatia
19 shared publications - Ivana Jurin
Department of Cardiovascular Diseases, University Hospital Dubrava, Zagreb, Croatia
17 shared publications - Mario Udovičić
Department of Cardiovascular Diseases, University Hospital Dubrava, 10000 Zagreb, Croatia
14 shared publications - Tomo Svaguša
Department of Cardiovascular Disease University Hospital Dubrava Zagreb Croatia
14 shared publications - Danijela Grizelj
Dubrava University Hospital, Zagreb, Croatia
13 shared publications - Hrvoje Falak
Dubrava University Hospital, Zagreb, Croatia
10 shared publications
Latest Publications
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 306
Can we do better in assessing velocity across the aortic valve?
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 306
Can we do better in assessing velocity across the aortic valve?
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 318
Pelacarsen in primary reduction of lipoprotein (a); single center experience in four patients
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 318
Pelacarsen in primary reduction of lipoprotein (a); single center experience in four patients
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 262
Beyond the phenotype: translating cardiomyopathy genetics into clinical decisions
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 262
Beyond the phenotype: translating cardiomyopathy genetics into clinical decisions
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 216
Beyond the angiogram: unmet lipid targets in chronic coronary syndrome
- 1 November 2026
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 21 (11-12) , 216
Beyond the angiogram: unmet lipid targets in chronic coronary syndrome
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 157
Muscular ventricular septal defect: which diagnostic test to trust when calculating shunt fraction?
- 1 April 2025
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 20 (5-6) , 157
Muscular ventricular septal defect: which diagnostic test to trust when calculating shunt fraction?
- Open Access
- 1 December 2024
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 74 (4) , 693-708
Prevalence and factors associated with potential clinically significant drug-drug interactions in patients with cardiovascular diseases at hospital admission
Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity globally. It is estimated that 17.9 million people died from CVDs in 2019, which represents 32 % of all deaths worldwide. Cardiovascular drugs are the most common medical intervention for the prevention of cardiovascular events. CV medications have many benefits however their application is often complicated by multimorbidity and polypharmacy. Drug-drug interactions (DDIs) can lead to adverse drug events, hospitalizations, prolonged hospital stays, increased healthcare costs, and increased risk of mortality. Hospital admission provides an opportunity for pharmacotherapy analysis and for identifying DDIs which can jeopardize medication safety. The aim of this study is to determine the type and prevalence of potential clinically significant DDIs in patients with CVD and to examine factors associated with exposure to DDIs. A prospective study was conducted at the Dubrava University Hospital at the Clinic of Cardiology during a 6-month period (September 2023 – February 2024). Demographic, clinical and pharmacotherapy data were collected for each patient. The first prescribed pharmacotherapy was analyzed. The research was approved by the Hospital’s Ethics Committee and each patient involved in the study signed an informed consent. Lexicomp ® Lexi-InteractTM Online (Lexi-Comp, Inc., USA) was used for DDI analysis. Poisson regression was used for regression analysis for determining risk factors associated with exposure to DDIs. Total of 151 patients admitted to Cardiology ward were included in the research, and the average age was 67 years. Patients had an average of 9 medications in their therapy and 8 diagnoses. Overall, 1268 potential clinically significant DDIs were determined, of which the most frequently determined interactions were grade C (90.9 %), then grade D (8.6 %) and grade X (0.6 %). CV medications were involved in 88 % DDIs. The most common interventions regarding identified DDIs included exclusion one of the drugs, dose adjustment, increased monitoring of signs of bleeding, cardiac disorders, hypoglycemia, CNS depression and rhabdomyolysis, blood pressure, markers of renal function and electrolyte status. Factors associated with the prevalence of potential clinically significant DDIs were decreased renal function, recent hospitalization, total number of comorbidities and polypharmacy. Specific comorbidities associated with DDIs were arrhythmia, heart failure, diabetes mellitus and disease of the respiratory system. A high prevalence of DDIs of CV medications in all categories of clinical significance was determined. Managing medication safety in specific patient groups with CVDs can represent a greater challenge regarding DDIs. Certain medical conditions, such as arrhythmia, heart failure, diabetes, and diseases of the respiratory system, multimorbidity, polypharmacy, impaired renal function and recent hospitalization are identified in this research as additional factors associated with DDIs occurrence in patients with CVDs at hospital admission. Hospital admission is one of the crucial points for managing medication safety. Clinical pharmacists should regularly analyze DDIs in prescribed pharmaco-therapy which enhances medication safety and also contributes to the quality of provided health care.
- 1 December 2024
- Published by Walter de Gruyter GmbH in Acta Pharmaceutica
- Vol. 74 (4) , 693-708
Open AccessPrevalence and factors associated with potential clinically significant drug-drug interactions in patients with cardiovascular diseases at hospital admission
Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity globally. It is estimated that 17.9 million people died from CVDs in 2019, which represents 32 % of all deaths worldwide. Cardiovascular drugs are the most common medical intervention for the prevention of cardiovascular events. CV medications have many benefits however their application is often complicated by multimorbidity and polypharmacy. Drug-drug interactions (DDIs) can lead to adverse drug events, hospitalizations, prolonged hospital stays, increased healthcare costs, and increased risk of mortality. Hospital admission provides an opportunity for pharmacotherapy analysis and for identifying DDIs which can jeopardize medication safety. The aim of this study is to determine the type and prevalence of potential clinically significant DDIs in patients with CVD and to examine factors associated with exposure to DDIs. A prospective study was conducted at the Dubrava University Hospital at the Clinic of Cardiology during a 6-month period (September 2023 – February 2024). Demographic, clinical and pharmacotherapy data were collected for each patient. The first prescribed pharmacotherapy was analyzed. The research was approved by the Hospital’s Ethics Committee and each patient involved in the study signed an informed consent. Lexicomp ® Lexi-InteractTM Online (Lexi-Comp, Inc., USA) was used for DDI analysis. Poisson regression was used for regression analysis for determining risk factors associated with exposure to DDIs. Total of 151 patients admitted to Cardiology ward were included in the research, and the average age was 67 years. Patients had an average of 9 medications in their therapy and 8 diagnoses. Overall, 1268 potential clinically significant DDIs were determined, of which the most frequently determined interactions were grade C (90.9 %), then grade D (8.6 %) and grade X (0.6 %). CV medications were involved in 88 % DDIs. The most common interventions regarding identified DDIs included exclusion one of the drugs, dose adjustment, increased monitoring of signs of bleeding, cardiac disorders, hypoglycemia, CNS depression and rhabdomyolysis, blood pressure, markers of renal function and electrolyte status. Factors associated with the prevalence of potential clinically significant DDIs were decreased renal function, recent hospitalization, total number of comorbidities and polypharmacy. Specific comorbidities associated with DDIs were arrhythmia, heart failure, diabetes mellitus and disease of the respiratory system. A high prevalence of DDIs of CV medications in all categories of clinical significance was determined. Managing medication safety in specific patient groups with CVDs can represent a greater challenge regarding DDIs. Certain medical conditions, such as arrhythmia, heart failure, diabetes, and diseases of the respiratory system, multimorbidity, polypharmacy, impaired renal function and recent hospitalization are identified in this research as additional factors associated with DDIs occurrence in patients with CVDs at hospital admission. Hospital admission is one of the crucial points for managing medication safety. Clinical pharmacists should regularly analyze DDIs in prescribed pharmaco-therapy which enhances medication safety and also contributes to the quality of provided health care.
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 499-500
A rare form of left atrial appendage tumor
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 499-500
A rare form of left atrial appendage tumor
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 504
The prevalence of atrial fibrillation in Croatia – from the past to the future
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 504
The prevalence of atrial fibrillation in Croatia – from the past to the future
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 501-502
Unicuspid aortic valve, accurate detection for timely intervention
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 501-502
Unicuspid aortic valve, accurate detection for timely intervention
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 498
How much can we trust MSCT coronarography?
- 1 November 2024
- Published by Medicinska Naklada d.o.o. in Cardiologia Croatica
- Vol. 19 (11-12) , 498
How much can we trust MSCT coronarography?